

## Special Issue

# Nanocarriers for Targeted Cancer Therapy in Personalised Nanomedicine

### Message from the Guest Editors

This Special Issue highlights the development and use of nanocarriers for targeted therapies in personalised medicine. Innovative and precision-based strategies for cancer treatment, involving customised nanovectors, play a crucial role in addressing what is often referred to as the 'disease of the century'. In this scenario, personalised nanomedicine is an emerging and inherently interdisciplinary field, promoting the development of next-generation nano-tools for targeted therapy and diagnosis, such as nanoparticles, nanocapsules, and nanomicelles. The publication of original research articles and reviews in this Special Issue will contribute to advancing scientific knowledge in personalised nanomedicine and support the clinical translation of nanocarrier-based approaches in oncology.

### Guest Editors

Prof. Dr. Stefano Loporatti

CNR NANOTEC—Istituto di Nanotecnologia, Via Monteroni, 73100 Lecce, Italy

Dr. Francesca Persano

Mathematics and Physics Department "Ennio De Giorgi", Università del Salento, Via Monteroni, 73100 Lecce, Italy

### Deadline for manuscript submissions

25 April 2026



## Journal of Personalized Medicine

an Open Access Journal  
by MDPI

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/si/243721](https://mdpi.com/si/243721)

*Journal of Personalized Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/jpm](https://mdpi.com/journal/jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/  
jpm](https://mdpi.com/journal/jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).